|
|
肺腺癌脑转移患者EGFR-TKI耐药后治疗的文献综述
|
Abstract:
驱动基因阳性肺腺癌患者口服靶向药物较传统化疗 + 免疫治疗相比，病人有更好的依从性，治疗效果更佳。然而国内外多项研究显示，药物耐药性不可规避。多种耐药机制使得少部分患者初始使用EGFR-TKIs时即对药物不敏感，或肿瘤在3个月内迅速进展，敏感患者长时间口服药物后也会出现耐药现象。因此耐药后治疗方案的选择对于患者预后十分重要。本文将收录的近15年国内外有关肺腺癌脑转移靶向药物耐药后治疗方案选择的文献总结，能给患者带来更好预后的治疗方案。
Compared with traditional chemotherapy and immunotherapy, patients with positive driver gene lung adenocarcinoma who take targeted drugs have better compliance and better therapeutic effect. However, many studies at home and abroad have shown that drug resistance is inevitable. Multiple resistance mechanisms cause that a small number of patients are insensitive to the drugs when they initially use EGFR-TKIs, or the tumor progresses rapidly within 3 months. Even sensitive patients may develop drug resistance after long-term oral administration of drugs. Therefore, the choice of treatment plan after drug resistance is very important for the prognosis of patients. This article summarizes the literature on the selection of treatment plans for targeted drugs for lung adenocarcinoma with brain metastasis in the past 15 years from both domestic and foreign sources, which can provide patients with better treatment plans for better prognosis.
| [1] | Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., et al. (2020) Systemic Treatment of Brain Metastases in Non-Small Cell Lung Cancer. European Journal of Cancer, 132, 187-198. https://doi.org/10.1016/j.ejca.2020.03.006 |
| [2] | Cella, D., Wen, P.Y., Ervin, C., Vallow, S., Gilloteau, I., DeMuro, C., et al. (2023) Understanding the Patient Experience and Treatment Benefits in Patients with Non-Small-Cell Lung Cancer with Brain Metastasis. Cancer Medicine, 12, 13637-13648. https://doi.org/10.1002/cam4.5975 |
| [3] | 刘婧如. 全身治疗方案对驱动基因阴性伴有症状脑转移肺腺癌患者预后的影响[D]: [硕士学位论文]. 济南: 山东学, 2023. |
| [4] | Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., et al. (2013) Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 19, 2240-2247. https://doi.org/10.1158/1078-0432.ccr-12-2246 |
| [5] | 乔晓娟. 1.肺癌耐药相关基因在化疗疗效评估的基础和临床研究. 2.晚期肺腺癌患者EGFR-TKI治疗耐药后治疗策略的临床分析[D]: [博士学位论文]. 北京: 北京市结核病胸部肿瘤研究所, 2015. |
| [6] | Sun, J., Ahn, M., Choi, Y., Ahn, J.S. and Park, K. (2013) Clinical Implications of T790M Mutation in Patients with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Lung Cancer, 82, 294-298. https://doi.org/10.1016/j.lungcan.2013.08.023 |
| [7] | Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382, 41-50. https://doi.org/10.1056/nejmoa1913662 |
| [8] | Tang, Z. and Lu, J. (2018) Osimertinib Resistance in Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies. Cancer Letters, 420, 242-246. https://doi.org/10.1016/j.canlet.2018.02.004 |
| [9] | 王俊, 冉凤鸣, 钱羽. 甲磺酸伏美替尼治疗非小细胞肺癌的研究进展[J/OL]. 肿瘤学杂志, 715-721. http://kns.cnki.net/kcms/detail/33.1266.R.20240918.1018.002.html, 2024-09-22. |
| [10] | Nishimura, T., Okano, T., Naito, M., Iwanaka, S., Ohiwa, A., Sakakura, Y., et al. (2021) Second-Line Therapy with First or Second-Generation Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with t790m-Negative or Unidentified Mutation. Thoracic Cancer, 12, 1067-1073. https://doi.org/10.1111/1759-7714.13870 |
| [11] | Wang, Y., Chen, R., Wa, Y., Ding, S., Yang, Y., Liao, J., et al. (2022) Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis from Non-Small Cell Lung Cancer. Frontiers in Immunology, 13, Article 829451. https://doi.org/10.3389/fimmu.2022.829451 |
| [12] | Rossi, A. and Galetta, D. (2022) Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations. Cancers, 14, Article 832. https://doi.org/10.3390/cancers14030832 |
| [13] | Corgnac, S., Malenica, I., Mezquita, L., Auclin, E., Voilin, E., Kacher, J., et al. (2020) CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. Cell Reports Medicine, 1, Article 100127. https://doi.org/10.1016/j.xcrm.2020.100127 |
| [14] | Yao, Z., Liao, W., Yang, C., Ho, C., Shih, J., Chen, K., et al. (2024) Real-World Analysis of Survival Outcomes in Advanced EGFR-Mutant NSCLC Patients Treated with Platinum-Pemetrexed after EGFR-TKI Treatment Failure. Journal of the Formosan Medical Association, 15, S0929-6646. https://doi.org/10.1016/j.jfma.2024.08.017 |
| [15] | Yamaguchi, H., Wakuda, K., Fukuda, M., Kenmotsu, H., Mukae, H., Ito, K., et al. (2021) A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis from NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116l). Journal of Thoracic Oncology, 16, 2121-2132. https://doi.org/10.1016/j.jtho.2021.07.026 |
| [16] | 马琳, 刁博文, 黄召勤, 等. 免疫检查点抑制剂在EGFR突变的非小细胞肺癌中的疗效及潜机制[J]. 癌症, 2023, 42(12): 614-631. |
| [17] | Fares, J., Ulasov, I., Timashev, P. and Lesniak, M.S. (2021) Emerging Principles of Brain Immunology and Immune Checkpoint Blockade in Brain Metastases. Brain, 144, 1046-1066. https://doi.org/10.1093/brain/awab012 |
| [18] | 周曙杰. 免疫检查点抑制剂在EGFR突变NSCLC脑转移患者TKIs耐药后的疗效分析[D]: [硕士学位论文]. 济南: 山东大学, 2023. |
| [19] | 杨明意. EGFR突变型晚期非小细胞肺癌TKI耐药后对免疫治疗的反应及预测性生物标物研究[D]: [硕士学位论文]. 广州: 华南理工大学, 2023. |
| [20] | 尹航. 驱动基因阳性非小细胞肺癌的免疫检查点抑制剂治疗的研究进展[J]. 实用临床医药杂志, 2023, 27(10): 144-148. |
| [21] | Garcia, J., Hurwitz, H.I., Sandler, A.B., Miles, D., Coleman, R.L., Deurloo, R., et al. (2020) Bevacizumab (Avastin) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article 102017. https://doi.org/10.1016/j.ctrv.2020.102017 |
| [22] | 焦书月, 张潇, 朱辉, 等. EGFR-TKI分别联合化疗和贝伐珠单抗治疗EGFR突变晚期非小细肺癌的效果比较[J]. 河南医学研究, 2021, 30(35): 6540-6544. |
| [23] | Hua, Y., Gao, D., Wang, K., Ding, X., Xu, W., Li, Y., et al. (2023) Bevacizumab Reduces Peritumoral Brain Edema in Lung Cancer Brain Metastases after Radiotherapy. Thoracic Cancer, 14, 3133-3139. https://doi.org/10.1111/1759-7714.15106 |
| [24] | Reck, M., Mok, T.S.K., Nishio, M., Jotte, R.M., Cappuzzo, F., Orlandi, F., et al. (2019) Atezolizumab Plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (impower150): Key Subgroup Analyses of Patients with EGFR Mutations or Baseline Liver Metastases in a Randomized, Open-Label Phase 3 Trial. The Lancet Respiratory Medicine, 7, 387-401. https://doi.org/10.1016/s2213-2600(19)30084-0 |
| [25] | 罗娟. 非小细胞肺癌EGFR-TKI继发性耐药的影响因素及耐药后治疗策略的临床研究[D]: [硕士学位论文]. 南昌: 南昌大学, 2019. |
| [26] | 王蓉, 郭人花, 卢凯华, 等. 肺腺癌EGFR-TKI耐药后继续靶向药联合化疗的临床疗效[J]. 南医科大学学报(自然科学版), 2018, 38(12): 1701-1705. |
| [27] | 詹琼, 周鑫莉, 黄若凡, 等. 贝伐单抗治疗EGFR野生型或EGFR-TKI耐药的肺腺癌脑转移疗效和安全性[J]. 肿瘤, 2016, 36(10): 1139-1145. |
| [28] | Li, X., Huang, H., Sun, Y., Jiang, Q. and Yu, Y. (2023) Immunotherapy Strategies for EGFR-Mutated Advanced NSCLC after EGFR Tyrosine-Kinase Inhibitors Failure. Frontiers in Oncology, 13, Article 1265236. https://doi.org/10.3389/fonc.2023.1265236 |
| [29] | Zheng, R.S., Chen, R., Han, B.F., Wang, S.M., Li, L., et al. (2024) Cancer Cadence and Mortality in China. Chinese Journal of Oncology, 46, 221-231. https://doi.org/10.3760/cma.j.cn112152-20240119-00035 |
| [30] | Lee, H., Chen, C., Chuang, H., Huang, Y. and Huang, M. (2019) Brain Surgery in Combination with Tyrosine Kinase Inhibitor and Whole Brain Radiotherapy for Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer with Brain Metastases. Scientific Reports, 9, Article No. 16834. https://doi.org/10.1038/s41598-019-53456-z |
| [31] | Li, L., Feng, M., Xu, P., Wu, Y.L., Yin, J., Huang, Y., et al. (2021) Stereotactic Radiosurgery with Whole Brain Radiotherapy Combined with Bevacizumab in the Treatment of Brain Metastases from NSCLC. International Journal of Neuroscience, 133, 334-341. https://doi.org/10.1080/00207454.2021.1916490 |
